Isolated cytokine receptor LICR-2
AssigneeLudwig Institute for Cancer Research
InventorsJean-Christophe Renauld, Helmut Fickenscher, Laure Dumoutier, Simon Hor
Life of this patent
Estimating the term…
Abstract
The invention relates to new members of the Class II cytokine receptor family, such as LICR-2. The new member binds to AK155, and mediates STAT activation.
Claims37
An isolated nucleic acid molecule which encodes a cytokine receptor, wherein the complementary nucleotide sequence of said isolated nucleic acid molecule, hybridizes, under stringent conditions, to SEQ ID NO:
- 7 or SEQ ID NO:
- 9.
A method for determining expression of a nucleic acid molecule which encodes a protein antagonist of AK155 binding protein in a sample, comprising contacting said sample with an oligonucleotide which hybridizes specifically, under stringent conditions to the nucleotide sequence of SEQ ID NO:
- 7 or SEQ ID NO:
- 9, hybridization thereto being indicative of expression of said nucleic acid molecule.
An isolated oligonucleotide consisting of from 17 to 100 contiguous nucleotides of SEQ ID NO:
- 7 or SEQ ID NO:
- 9.
A method for identifying an agent which modulates binding of AK155 to LICR-2, comprising combining AK155 and LICR-2 or a fragment of LICR-2 which binds to AK155, together with said agent, measuring interaction between AK155 and LICR-2 or binding fragment thereof, and comprising measured interaction to interaction between AK155 and LICR-2 or binding fragment thereof in absence of said agent, differences therebetween being indicative of said agent being a modulator of binding between AK155 and LICR-2.
Dependencies are inferred from the claim text.